Contains Nonbinding Recommendations

Guidance on Didanosine

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Didanosine

Form/Route: Delayed-Release Capsules Enteric-Coated Beadlets/Oral

Recommended studies: 1 study

- Type of study: Fasting
- Design: Single-dose, two-treatment, two-period crossover *in-vivo*
- Strength: 400 mg
- Subjects: Normal healthy males and females, general population

Additional Comments:

---

Analytes to measure (in appropriate biological fluid): Didanosine in plasma using an achiral method

Bioequivalence based on (90% CI): Didanosine

Waiver request of in-vivo testing: 125 mg, 200 mg, and 250 mg, based on (i) acceptable bioequivalence studies on the 400 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008